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Objectives. The purpose of this study was to investigate whether
functional abnormalities in coronary vasomotion are present in
young healthy asymptomatic men fulfilling the World Health
Organization (WHO) criteria for borderline hypertension.
Background. Previous studies have reported reduced coronary
flow reserve in middle-aged subjects with sustained hypertension
and hypertension-induced microvascular heart disease or left
ventricular hypertrophy.
Methods. Myocardial blood flow was measured at baseline and
during dipyridamole-induced hyperemia by means of positron
emission tomography and oxygen-15–labeled water in asymptom-
atic young men with borderline hypertension (group 1: n 5 16,
mean 6 SD age 37 6 4 years, 24-h ambulatory blood pressure
135 6 10/81 6 9 mm Hg) and matched healthy control subjects
(group 2: n 5 19, age 35 6 3 years, 24-h ambulatory blood
pressure 119 6 8/69 6 8 mm Hg, p < 0.001). Left ventricular (LV)
mass, dimensions and function were measured by echocardiogra-
phy.
Results. LV mass, dimensions and diastolic function were
similar in the study groups. Baseline myocardial blood flow was
similar (0.83 6 0.21 vs. 0.80 6 0.22 ml/g per min, group 1 vs.
group 2, respectively, p 5 NS), and a significant increase in flow
was detected after dipyridamole infusion (0.56 mg/kg body weight
in 4 min intravenously) in both groups. However, the flow
response to dipyridamole was significantly lower in group 1,
leading to lower hyperemic flow in group 1 than in group 2 (2.85 6
1.20 vs. 3.80 6 1.44 ml/g per min, respectively). Consequently, the
coronary flow response was lower in hypertensive than in normo-
tensive men (3.46 6 1.23 vs. 4.99 6 2.5 ml/g per min, group 1 vs.
group 2, respectively, p < 0.05).
Conclusions. These results demonstrate reduced coronary re-
activity present in young asymptomatic men with borderline
hypertension and no signs of hypertension-induced angina or left
ventricular hypertrophy. Because baseline basal myocardial blood
flow was unchanged, the reduction in coronary flow reserve
depends on an impaired maximal vasodilator capacity.
(J Am Coll Cardiol 1998;32:147–53)
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Reduced coronary flow reserve has been suggested to be one
of the earliest abnormalities associated with coronary artery
disease (1). Previous studies have reported reduced coronary
flow reserve in hypertensive subjects with (2–4) or without left
ventricular (LV) hypertrophy (3–10). However, all these stud-
ies were limited to hypertensive patients with symptoms sug-
gestive of coronary artery disease because coronary flow
reserve measurements in these earlier studies required invasive
coronary catherization. Recently, a less invasive transesopha-
geal echocardiographic method was applied (11), and reduced
coronary reserve was also reported in asymptomatic, previ-
ously treated hypertensive subjects without LV hypertrophy.
However, in that study only 6 of the 33 studied middle-aged
hypertensive subjects (mean age 58 years) did not have LV
hypertrophy or symptoms of angina. Thus, although previous
studies have demonstrated abnormal coronary flow responses
in middle-aged subjects with sustained hypertension or with
hypertension-induced microvascular angina, it is unknown
whether abnormalities in functional coronary reactivity are
present in young asymptomatic subjects with borderline hyper-
tension. If this is the case, it would suggest active recognization
and intervention of borderline hypertension because antihy-
pertensive treatment has been shown to improve impaired
coronary flow reserve (5,9,12,13) and to reduce symptoms of
microvascular angina in patients with essential hypertension
(9).
For clinical risk stratification studies, a safe technique with
minimal invasiviness, allowing detection of early abnormalities
and a direct comparison with a healthy control group, is
needed. Use of positron emission tomography (PET) and
oxygen-15–labeled water ([15O]H2O) is currently the most
accurate nonivasive approach available for measuring myocar-
dial perfusion (14). Additionally, a marked correlation has
been demonstrated (15) between myocardial perfusion reserve
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and the degree of angiographically documented coronary
artery disease using PET, [15O]H2O and dipyridamole as a
coronary vasodilatatory agent. Using nonivasive PET imaging,
our group has recently reported alterations in functional
vascular reactivity in young men with familial hypercholester-
olemia (16) and found the number of conventional coronary
artery risk variables to be related to coronary flow reserve (17).
In the present study PET, [15O]H2O and dipyridamole were
used to quantitate coronary reactivity in healthy young men
selected from participants of an epidemiologic study. Two
subject groups were selected on the basis of blood pressure
values—one fulfilling World Health Organization (WHO)
criteria for borderline hypertension and one with normal blood
pressure values.
Methods
Subjects. The study subjects were recruited from families
participating in the Special Turku Coronary Risk Factor
Intervention Project (STRIP) baby project (18) that sought to
study the effects of dietary intervention on coronary risk factors
in young children. We used data that had been previously
obtained from the children’s fathers. Young (,40 years old),
lean (body mass index ,28 kg/m2), nonsmoking and nondia-
betic men were included. Subjects had no medication. Two
groups of subjects were selected on the basis of earlier blood
pressure measurements taken on three previous occasions ;1
year apart. Group 1 included men with blood pressure values
classified by WHO as borderline hypertension (systolic blood
pressure 140 to 160 mm Hg or diastolic blood pressure 90 to
95 mm Hg, or both) (19). Group 2 included men with normal
blood pressure (,140/85 mm Hg) for all measurements. The
two study groups were matched for age, body mass index and
serum cholesterol concentration. Family history of coronary
heart disease was comparable between the groups (two sub-
jects had a positive family history of early coronary heart
disease in group 1 and one subject in group 2). Family history
was considered to be positive if documented coronary artery
disease was present in at least one of the subject’s first-degree
relatives ,50 years old (male relatives) or ,60 years old
(female relatives). The study protocol was successfully carried
out in 16 men from group 1 and 19 men from group 2.
Study design. Study subjects were instructed to avoid all
caffeine-containing drinks and foods for 12 h before the PET
studies. Myocardial perfusion was measured twice—once at
rest and once after administration of dipyridamole. Heart rate
and the electrocardiogram (ECG) were monitored continu-
ously during the studies. Blood pressure was monitored with an
automatic oscillometric blood pressure monitor (OMRON
HEM-705C, Omron Healthcare, Hamburg, Germany) during
the PET study. The study protocol was accepted by the ethics
committee of Turku University Central Hospital. Each subject
provided written informed consent.
Production of oxygen-15–labeled carbon monoxide and
[15O]H2O. For production of oxygen-15 a low-energy deu-
teron accelerator (Cyclone 3) was used (Ion Beam Applica-
tion, Louvain-la-Neuve, Belgium). Oxygen-15–labeled carbon
monoxide ([15O]CO) was produced using conventional meth-
ods (20). [15O]H2O was produced using dialysis techniques in
a continuously working water module (21). Production for CO
and water were 2.5 and 1.7 GBq/min, respectively. Sterility and
pyrogenity tests for water and chromatographic analysis for
gases were performed to verify the purity of the products.
Image acquisition, processing and corrections. Patients
were positioned supine in an 15-slice ECAT 931/08-12 tomo-
graph (Siemens/CTI) with a measured axial resolution of 6.7
and 6.5 mm in-plane. To correct for photon attenuation a
transmission scan was performed for 20 min, before the
emission scan, with a removable ring source containing
germanium-68. After the transmission scan, the subjects’ nos-
trils were closed, and they inhaled [15O]CO for 2 min through
a three-way inhalation flap-valve (0.14% CO mixed with room
air). After the inhalation, 2 min were allowed for CO to
combine with hemoglobin in red blood cells before a static scan
for 4 min was started. During the scan period, three blood
samples were drawn at 2-min intervals, and blood radioactivity
was measured immediately with a well counter (Bicron 3MW3/
3). A 10-min period was allowed for [15O]CO radioactive decay
before the flow measurements.
Flow was measured at baseline and 2 min after the end of
intravenous administration of dipyridamole (0.56 mg/kg body
weight over 4 min). [15O]H2O was injected intravenously over
2 min, and dynamic scanning was started for 6 min (6 3 5 s, 6 3
15 s, 8 3 30 s). All data were corrected for deadtime, decay and
photon attenuation and were reconstructed into a 128 3 128
matrix. The final in-plane resolution in the reconstructed and
Hann-filtered (0.3 cycles/s) images was 9.5 mm (full-width
half-maximum).
Calculation of regional blood flow. Regions of interest
(ROIs) were drawn in the lateral, anterior and septal walls of
the left ventricle in four representative transaxial slices in each
study. The ROIs outlined in the baseline images were copied
to the images obtained after dipyridamole administration.
Values of regional myocardial blood flow (in ml/g tissue per
min) were calculated according to the previously published
method using the single-compartment model (22,23).
The arterial input function was obtained from the LV
time–activity curve by means of a previously validated method
Abbreviations and Acronyms
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(24), in which corrections were made for the limited recovery
of the LV ROI and the spillover from the myocardial signals.
No regional differences were found in myocardial perfusion.
Therefore, to enhance accuracy and statistic significance of the
flow measurements, the average blood flow of global myocar-
dium was calculated and used in further analysis. Coronary flow
reserve was defined as the ratio of myocardial blood flow after
dipyridamole to baseline flow.
Echocardiographic examination. All echocardiographic
recordings and analyses were performed by the same investi-
gator (O.T.R.) using a commercially available ultrasound
scanner (Acuson 128XP/10). The study subjects rested
.15 min before they were examined in the left lateral decub-
itus position. After echocardiographic study, blood pressure
was measured. Standard echocardiographic views of the left
ventricle were obtained, and cardiac dimensions were mea-
sured. The following variables were used for echocardio-
graphic measurements of the left ventricle; LV end-diastolic
diameter (LVDd); LV end-systolic diameter (LVDs); LV
posterior wall thickness in diastole (LVPWd); LV posterior
wall thickness in systole (LVPWs). Left ventricular mass
(LVM) was calculated as follows: LVM 5 1.04 3 [(IVSd 1
LVPWd 1 LVDd)3 2 LVDd3] 2 13.6, where IVSd 5 inter-
ventricular septal thickness during diastole (25). LVM index
(LVMI) was expressed as LVM per body surface area (g/m2).
LV systolic function was assessed by calculating the percent
fractional shortening of the left ventricle as (LVDd 2 LVDs)/
LVDd 3 100 and LV ejection fraction (percent) as (LV
diastolic volume 2 LV systolic volume)/LV diastolic volume.
LV meridional peak systolic wall stress (PSWS) (103 dynes/
cm2) was calculated by the following formula: PSWS 5 [0.86
[(0.334 3 SBP 3 LVDd)/(LVPWd 1 (1 1 LVPWd/LVDd))]
2 27] 3 103, where SBP 5 systolic blood pressure (26). From
the mitral flow velocity tracings, the early (E) and late (A)
mitral flow peak velocities were measured. LV diastolic func-
tion was assessed by calculating the mitral Doppler peak early
diastolic blood flow velocity (E) to peak late diastolic flow
velocity (A) ratio (E/A ratio).
Ambulatory blood pressure measurements. Ambulatory
blood pressure was monitored using an auscultatory method
(Novacor Diasys). The recorder was installed by an experi-
enced technician. The accuracy and reproductibility of this
device have been previously reported to be excellent (27). The
device was installed in the left arm in the morning, and blood
pressure was verified against a mercury sphygmomanometer in
the supine, sitting and standing positions both when installing
and taking off the automatic device. The ambulatory blood
pressure reading was aimed at within a 5-mm Hg limit from the
simultaneous auscultatory reading. Ambulatory blood pressure
was recorded at 20-min intervals during the daytime and at
60-min intervals during the night.
Analytic procedures. Venous blood samples were taken
after 12 h of overnight fasting during the same week as the
PET study. Plasma glucose was determined by the glucose
oxidase method (28). Serum insulin was measured by a radio-
immunoassay kit (Pharmacia, Uppsala, Sweden). All lipid
determinations were done in the laboratory of Turku Univer-
sity Hospital. Serum total cholesterol, high density lipoprotein
(HDL) cholesterol and triglyceride concentrations were mea-
sured using standard enzymatic methods (Boehringer Mann-
heim GmbH, Mannheim, Germany) with a fully automated
analyzer (Hitachi 704, Hitachi Ltd., Tokyo, Japan). HDL
cholesterol was measured after polyethyleneglycol (molecular
weight 6,000, final concentration 10%) precipitation (29). The
low density lipoprotein (LDL) cholesterol concentration was
calculated by using the Friedewald formula (30).
Statistical methods. Results are expressed as mean
value 6 SD. The difference in flow values between the groups
and the response to dipyridamole and the interaction of these
two variables were statistically tested using analysis of variance
of repeated measures (31). Associations between risk and flow
variables were studied by calculating the Pearson correlation
coefficients. A p value ,0.05 was considered statistically sig-
nificant. All statistical tests were performed with the SAS
statistical analysis system (SAS Institute).
Results
Study subjects. The characteristics of the subjects are
shown in Table 1. Blood pressures were higher in group 1 when
measured as office blood pressures before the PET study or as
24-h ambulatory blood pressure (Table 1). There were no
differences in serum cholesterol, HDL cholesterol, LDL
cholesterol, insulin or plasma glucose concentrations between
the study groups (Table 1). The group 1 serum triglyceride
concentration was slightly higher than that in group 2 (2.0 6
1.0 vs. 1.3 6 0.8 mmol/liter, group 1 vs. group 2, respectively,
p , 0.05).
LVM and LV dimensions and early diastolic filling patterns
were similar in the study groups (Table 2). LV ejection fraction
and fractional shortening were normal in both groups but were
Table 1. Clinical Characteristics of Study Subjects
Group 1
(n 5 16)
Group 2
(n 5 19)
p
Value
Age (yr) 37 (4) 35 (3) NS
BMI (kg/m2) 26.1 (2.5) 25.8 (2.0) NS
SBP (mm Hg) 137 (22) 114 (14) , 0.01
DBP (mm Hg) 82 (10) 63 (8) , 0.01
SBP24h (mm Hg) 135 (10) 119 (8) , 0.001
DBP24h (mm Hg) 81 (9) 69 (8) , 0.001
FS chol (mmol/liter) 5.55 (1.02) 5.11 (0.80) NS
FS HDL chol (mmol/liter) 1.11 (0.17) 1.13 (0.26) NS
FS TGs (mmol/liter) 2.0 (1.0) 1.3 (0.8) , 0.05
FS LDL cholesterol (mmol/liter) 3.5 (0.9) 3.4 (0.8) NS
FP glucose (mmol/liter) 5.3 (0.6) 5.1 (0.6) NS
FS insulin (mU/liter) 10.3 (4.5) 8.5 (3.6) NS
Data presented are mean value (SD). BMI 5 body mass index; DBP 5
diastolic blood pressure; DBP24h 5 24 h ambulatory diastolic blood pressure;
FS 5 fat-soluble; HDL chol 5 high density lipoprotein cholesterol; LDL chol 5
low density lipoprotein cholesterol; SBP 5 systolic blood pressure; SBP24h 5
24-h ambulatory systolic blood pressure; TGs 5 triglycerides.
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significantly higher in group 1 (Table 2). LV wall stress was
higher in group 1 (205 6 36 3 103 dynes/cm2) than in group 2
(183 6 6 3 103 dynes/cm2, p , 0.05).
Hemodynamic measurements during PET. Blood pressure
and rate–pressure product were higher in subjects with mild
hypertension both basally and during vasodilation (Table 3).
No difference in heart rate was detected (Table 3). Dipyrida-
mole administration induced a significant increase in heart rate
and rate–pressure product in both groups, and the response to
dipyridamole was similar in both groups (Table 3).
Myocardial blood flow, coronary flow reserve and vascular
resistance. Basal myocardial blood flow was similar in both
study groups (0.83 6 0.21 vs. 0.81 6 0.21 ml/g per min, group
1 vs. group 2, respectively, p 5 NS). Dipyridamole infusion
increased flow significantly in both groups (p , 0.001): in
group 1 by 2.02 6 0.93 ml/g per min (p , 0.001) and in group
2 by 3.01 6 1.22 ml/g per min (p , 0.001) (Fig. 1), but the effect
of dipyridamole was different between the groups (interaction
between the study groups and the response to dipyridamole,
p , 0.05). During maximal vasodilation, myocardial blood flow
was lower in group 1 than in group 2 (2.85 6 1.20 vs. 3.80 6
1.44 ml/g per min, group 1 vs. group 2, respectively, p , 0.05).
Subsequently, coronary flow reserve was significantly lower in
borderline than in normotensive subjects (3.46 6 1.23 vs.
4.99 6 2.50, respectively, p , 0.05) (Fig. 2). Coronary flow
reserve correlated inversely with systolic and diastolic 24-h
ambulatory blood pressure values (coronary flow reserve vs.
24-h systolic blood pressure: r 5 20.35, p , 0.05; coronary
flow reserve vs. 24-h diastolic blood pressure: r 5 20.35, p ,
0.05) and with systolic and diastolic daytime ambulatory blood
pressure values in the pooled data (coronary flow reserve vs.
daytime systolic blood pressure: r 5 20.36, p , 0.05; coronary
flow reserve vs. daytime diastolic blood pressure: r 5 20.36,
p , 0.05). When the groups were analyzed separately, no
correlation was found between coronary flow reserve and
blood pressure values in group 1. However, in group 2,
significant inverse correlations were found between coronary
flow reserve and systolic 24-h ambulatory blood pressure
(r 5 20.48, p , 0.05) and systolic daytime ambulatory blood
pressure (r 5 20.51, p , 0.05). No significant associations
were found between flow variables and serum lipoprotein
levels.
Discussion
Abnormal coronary flow reserve has been previously reported
in middle-aged hypertensive patients with hypertension-induced
microvascular angina (3–9) or with hypertension-induced LV
Table 2. Left Ventricular Characteristics
Group 1
(n 5 16)
Group 2
(n 5 19)
p
Value
LVM (g) 189 (36) 188 (41) NS
LVMI (g/m2) 92 (16) 93 (22) NS
SEd (mm) 0.8 (0.1) 0.8 (0.1) NS
SEs (mm) 1.4 (0.2) 1.3 (0.1) NS
LVPWd (mm) 0.8 (0.1) 0.8 (0.1) NS
LVPWs (mm) 1.6 (0.2) 1.5 (0.1) NS
LVDd (mm) 5.4 (0.3) 5.4 (0.3) NS
LVDs (mm) 3.3 (0.4) 3.5 (0.3) NS
LVFS (%) 39.3 (6.0) 35.7 (3.8) , 0.05
LVEF (%) 69 (7) 64 (5) , 0.05
E/A 1.4 (0.3) 1.4 (0.3) NS
Wall stress (103 dynes/cm2) 206 (36) 183 (26) , 0.05
Data presented are mean value (SD). E/A 5 ratio of early (E) to late (A)
mitral flow peak velocities; LVDd 5 left ventricular diameter in diastole;
LVDs 5 left ventricular diameter in systole; LVEF 5 left ventricular ejection
fraction; LVFS 5 left ventricular fractional shortening; LVM 5 left ventricular
mass; LVMI 5 left ventricular mass index; LVPWd 5 left ventricular posterior
wall in diastole; LVPWs 5 left ventricular posterior wall in systole; SEd 5
septum in diastole; SEs 5 septum in systole.
Table 3. Hemodynamic Data During Positron Emission Tomography
HR (beats/min) SBP (mm Hg) DBP (mm Hg)
HR–SBP Product
(mm Hg 3 beats/min)
Rest Dipy Rest Dipy Rest Dipy Rest Dipy
Change
(%)
Group 1 (n 5 16) 63 (7) 84 (12)* 137 (22) 142 (25) 82 (10) 83 (11) 8,619 (1,851) 12,012 (3,169)* 39 (16)
Group 2 (n 5 19) 61 (8) 78 (9)* 114 (14)† 115 (13)† 63 (8)† 66 (8)† 6,864 (1,122)† 9,059 (1,664)*† 32 (20)
*p , 0.05, baseline versus after dipyridamole. †p , 0.001, group 1 versus group 2. Data presented are mean value (SD). Dipy 5 after dipyridamole administration.
Figure 1. Myocardial blood flow at baseline and during dipyridamole-
induced hyperemia. The myocardial blood flow response to dipyrida-
mole was significantly lower in group 1 than in group 2 (p , 0.05).
Triangles 5 individual flow values of the study subjects.
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hypertrophy (2–4). Recently, coronary flow reserve has also
been reported (11) to be reduced in a small group of asymp-
tomatic previously treated hypertensive subjects without LV
hypertrophy. However, in that study only 6 of the 33 previously
treated middle-aged hypertensive subjects (mean age 58 years)
were asymptomatic and had a normal LVM. Thus, to our
knowledge, the present study is the first to show that a
significant reduction in coronary reactivity is present in young
asymptomatic men with borderline hypertension and normal
LVM.
Dipyridamole as a vasoactive agent. We used dipyridamole
as a vasoactive agent to test coronary vascular function.
Dipyridamole increases interstitial adenosine concentration in
vascular smooth muscle cells and leads to relaxation of coro-
nary resistance vessels (32), and thus the increment in coronary
blood flow induced by dipyridamole has been suggested to be
primarily endothelium independent. However, increased shear
stress associated with increased flow is found to induce release
of vasodilating substances from endothelial cells (33) and to
elicit more prominent vasodilation in the vessels with pre-
served endothelial function. Indeed, in several studies (34–36)
endothelium-dependent coronary vasodilation has been found
to be associated with flow responses induced by adenosine or
dipyridamole. Therefore, the coronary flow response as as-
sessed by intravenous dipyridamole infusion, most likely re-
flects the combined effect of vascular smooth muscle relaxation
and endothelial-mediated vasodilatory function and can be
used as an integrating measure of coronary reactivity (1,15,37).
Factors that may impair coronary flow reserve in essential
hypertension. In the present study reduced coronary flow
reserve was observed in young asymptomatic men with border-
line hypertension, although basal myocardial blood flow and
LVM and function were normal. These findings raise the
possibility that reduced endothelial vasodilation or vascular
smooth muscle cell relaxation, or both, is present in borderline
hypertension because the present findings are not explained by
changes in basal blood flow or by hypertensive heart disease. In
experimental animal models of hypertension, reduced release
of endothelium-derived nitric oxide or hyperpolarizing factor
(38), augmented release of endothelium-derived constricting
factors (39) and inactivation of endothelium-derived relaxing
factors (40) have been reported. These previous experimental
findings have been supported by a recent report of reduced
basal nitric oxide synthesis in hypertensive subjects (41),
suggesting that endothelial dysfunction is coupled with dimin-
ished basal nitric oxide production in essential hypertension.
The reduced coronary vasodilator reserve in patients with
sustained hypertension has been suggested to be due to a
combination of impaired endothelium-dependent vasodilation
and structural abnormalities (11). Abnormal endothelium-
dependent coronary vasodilation in response to intracoronary
infusion of acetylcholine has been demonstrated in hyperten-
sive subjects with angina but angiographically normal coronary
arteries (7,8). A recent study (9) suggested that the diminished
endothelium-dependent dilation of resistance coronary arter-
ies in hypertensive subjects is related to a generalized endo-
thelial abnormality, but that diminished endothelium-
dependent dilation of large epicardial coronary arteries is
related to a selective abnormality in the muscarinic receptors
of the endothelium. Structural abnormalities, such as alter-
ations of intramyocardial arteries (42,43), increased perivascu-
lar fibrosis and increased myocardial fibrosis (41), have been
suggested to explain part of the reduced coronary dilatory
capacity in hypertensive subjects with microvascular angina. In
addition to these structural changes, extravascular compres-
sion of hypertrophied myocardium and inadequate angiogen-
esis (44) may also explain reduced coronary reactivity in
patients with essential hypertension and LV hypertrophy.
Vascular reactivity and cardiovascular risk status. The
subjects of the present study were all nonsmokers and nondi-
abetic. Age, body mass index, serum total cholesterol, HDL
cholesterol, LDL cholesterol, insulin and plasma glucose con-
centrations and family history of coronary heart disease were
comparable between the study groups. Serum triglyceride
concentrations were slightly higher in hypertensive than in
control subjects. However, in accordance with previous studies
(1,17), no association was found between triglyceride concen-
tration and flow reserve in the present study. Thus, it is unlikely
that the slightly higher triglyceride concentrations in the
hypertensive subjects would have acted as a confounding
factor. LV systolic function was normal in both study groups
but was higher in the borderline hypertensive than in the
control subjects. This finding is similar to previous studies
(45–48) reporting enhanced LV systolic performance in some
subjects with primary hypertension.
Limitations of the study. In the present study, only men
with borderline hypertension were enrolled. Whether the same
results can be extrapolated to female subjects of similar age
and similar blood pressure values remains to be shown. We
interpreted the present findings of reduced coronary reactivity
to reflect reduced endothelial vasodilation or impaired vascu-
lar smooth muscle cell relaxation, or both, yet the exact
mechanisms responsible for the hypertension-associated re-
duction in the ability of dipyridamole to induce coronary
vasodilation remains to be determined. Although we studied
healthy young asymptomatic subjects, coronary angiography or
Figure 2. Coronary flow reserve in groups 1 and 2.
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intracoronary ultrasound was not performed, and thus we
cannot exclude that the presence of more advanced early-stage
atherosclerosis might also explain the present finding of re-
duced coronary reactivity.
Conclusions. The present study demonstrates reduced
maximal coronary flow and flow reserve after dipyridamole
administration in young asymptomatic men with borderline
hypertension. Additionally, coronary flow reserve was related
to ambulatory 24-h blood pressure values, supporting the
concept that the presence of mildly elevated blood pressure is
associated with an abnormal coronary flow response. Never-
theless, the prognostic value of these early changes in asymp-
tomatic subjects remains to be defined by future studies.
We thank the staff of Turku PET Centre for excellent technical assistance.
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